212 related articles for article (PubMed ID: 4247823)
21. [Fibrinolysis].
Levy G; Michault A; Jamet M
Ann Anesthesiol Fr; 1978; 19(8):703-8. PubMed ID: 31114
[TBL] [Abstract][Full Text] [Related]
22. Exploration of intraglomerular phenomena by measurement of the level of fibrin degradation products in the renal vein blood.
Conte J; Boneu B; Mignon-Conte ; Suc JM
Perspect Nephrol Hypertens; 1973; 1 Pt 2(0):915-26. PubMed ID: 4807811
[No Abstract] [Full Text] [Related]
23. [Detection of serum fibrinogen degradation products using Merskey's technic, Apropos of 169 cases].
Kolodié L; Seigneurin D; Micouin C; Hollard D
Pathol Biol (Paris); 1974 Nov; 22 suppl():66-71. PubMed ID: 4219980
[No Abstract] [Full Text] [Related]
24. Experimental study of rabbit fibrinogen degradation products. Influence of plasminogen level for the interpretation of serum concentration of fibrinogen degradation products in consumption coagulopathies.
Soria J; Soria C; Vairel E; Prost RJ; Warneson G
Thromb Diath Haemorrh; 1973 Feb; 29(1):115-21. PubMed ID: 4267735
[No Abstract] [Full Text] [Related]
25. Fibrinogen degradation products: a critical study of two assay methods.
Thuot C; Larrieu MJ
Rev Eur Etud Clin Biol; 1971; 16(1):27-34. PubMed ID: 4252113
[No Abstract] [Full Text] [Related]
26. [Fibrin degradation products (FDP) and fibrinolytic activity of blood in various acute and chronic diseases].
Kotschy M
Folia Haematol Int Mag Klin Morphol Blutforsch; 1976; 103(3):425-30. PubMed ID: 63429
[No Abstract] [Full Text] [Related]
27. The preparation and evaluation of a standardized fibrin plate for the assessment of fibrinolytic activity.
Bishop R; Ekert H; Gilchrist G; Shanbrom E; Fekete L
Thromb Diath Haemorrh; 1970 May; 23(2):202-10. PubMed ID: 4246603
[No Abstract] [Full Text] [Related]
28. The hematologic consequences of thrombolytic therapy.
Fletcher AP; Alkjaersig NK
Prog Hematol; 1986; 14():183-200. PubMed ID: 2935903
[No Abstract] [Full Text] [Related]
29. [Evaluation of several parameters of coagulation in liver cirrhosis: disseminated intravascular coagulation or pseudo-disseminated intravascular coagulation?].
Petrella V; Parachini F; Rigotti T; Galimberti M; Cusumano S
Minerva Med; 1988 Mar; 79(3):193-8. PubMed ID: 3362400
[TBL] [Abstract][Full Text] [Related]
30. [Circulating levels of products of fibrinogen and fibrin monomer degradation in liver cirrhosis].
Rocha E; López Borrasca A
Rev Med Univ Navarra; 1974; 18(3-4):143-7. PubMed ID: 4471076
[No Abstract] [Full Text] [Related]
31. A review of the basic mechanisms of fibrinogen to fibrin conversion and of fibrinolysis: intravascular coagulation versus primary fibrinolysis.
Colick JA; Fisher LM
Va Med Mon (1918); 1970 May; 97(5):310-4 passimass. PubMed ID: 4276992
[No Abstract] [Full Text] [Related]
32. Hyperfibrinolysis resulting from clotting activation in patients with different degrees of cirrhosis. The CALC Group. Coagulation Abnormalities in Liver Cirrhosis.
Violi F; Ferro D; Basili S; Quintarelli C; Musca A; Cordova C; Balsano F
Hepatology; 1993 Jan; 17(1):78-83. PubMed ID: 8423044
[TBL] [Abstract][Full Text] [Related]
33. High plasma fibrinogen level is associated with poor clinical outcome in DIC patients.
Wada H; Mori Y; Okabayashi K; Gabazza EC; Kushiya F; Watanabe M; Nishikawa M; Shiku H; Nobori T
Am J Hematol; 2003 Jan; 72(1):1-7. PubMed ID: 12508260
[TBL] [Abstract][Full Text] [Related]
34. Fibrinogen-fibrin degradation products in uterine and peripheral blood during Caesarean section.
Hahn L
Acta Obstet Gynecol Scand Suppl; 1974; 28():1-7. PubMed ID: 4599651
[No Abstract] [Full Text] [Related]
35. [Diagnostic significance of proteolytic breakdown products of fibrinogen and fibrin].
Heene DL; Genth K
Internist (Berl); 1984 Feb; 25(2):93-101. PubMed ID: 6231262
[No Abstract] [Full Text] [Related]
36. The fibrinolytic enzyme system in haematological malignancy.
Dawson AA; Ogston D; Douglas AS
Bibl Anat; 1973; 12():272-8. PubMed ID: 4597632
[No Abstract] [Full Text] [Related]
37. Coagulation studies of menopausal women taking estrogen replacement.
Beller FK; Nachtigall L; Rosenberg M
Obstet Gynecol; 1972 May; 39(5):775-8. PubMed ID: 4260072
[No Abstract] [Full Text] [Related]
38. [Hemagglutination inhibition (Merskey's test) in consumption coagulopathies. Apropos of 101 patients].
Soria J; Soria C; Yver J; Girard ML; Samama M; Bilski-Pasquier G
Presse Med (1893); 1971 May; 79(22):1003-6. PubMed ID: 5281042
[No Abstract] [Full Text] [Related]
39. [Analytical methods of study of the system of fibrinolysis (plasminogen proactivators-activators, plasminogen-plasmin, antiplasmins, antiactivators) (literature review)].
Guseĭnov ChS; Golovastova GI; Gorelova AM; Cherenkova GM; Mikhailova ND
Lab Delo; 1976; (5):276-83. PubMed ID: 62085
[No Abstract] [Full Text] [Related]
40. Do plasma biomarkers of coagulation and fibrinolysis differ between patients who have experienced an acute myocardial infarction versus stable exertional angina?
Itakura H; Sobel BE; Boothroyd D; Leung LL; Iribarren C; Go AS; Fortmann SP; Quertermous T; Hlatky MA;
Am Heart J; 2007 Dec; 154(6):1059-64. PubMed ID: 18035075
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
